Scarica l'app Stockscreener
77.83
1.28%
0.90
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$76.93
Aprire:
$77.2
Volume 24 ore:
1.90M
Relative Volume:
0.44
Capitalizzazione di mercato:
$45.73B
Reddito:
$5.69B
Utile/perdita netta:
$4.14B
Rapporto P/E:
11.18
EPS:
6.96
Flusso di cassa netto:
$577.90M
1 W Prestazione:
-0.88%
1M Prestazione:
-0.17%
6M Prestazione:
+2.52%
1 anno Prestazione:
+17.43%
Intervallo 1D:
$76.62
$77.98
Intervallo di 1 settimana:
$76.07
$79.40
Portata 52W:
$64.00
$83.00
Edwards Lifesciences Corp Stock (EW) Company Profile
Nome
Edwards Lifesciences Corp
Settore
Industria
Telefono
(949) 250-2500
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Confronta EW con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
77.89 | 45.89B | 5.69B | 4.14B | 577.90M | 6.96 |
|
ABT
Abbott Laboratories
|
129.21 | 228.63B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.71 | 152.25B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
378.43 | 144.00B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.96 | 118.82B | 33.54B | 4.66B | 5.19B | 3.62 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-04-24 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Aggiornamento | Stifel | Hold → Buy |
| 2025-01-16 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-31 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | Truist | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-02-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-28 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-03-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Downgrade | Bernstein | Outperform → Underperform |
| 2023-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Downgrade | Stifel | Buy → Hold |
| 2022-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Iniziato | Mizuho | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-29 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Iniziato | Truist | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-03-16 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-27 | Reiterato | Citigroup | Buy |
| 2022-01-27 | Reiterato | Evercore ISI | Outperform |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | Stifel | Buy |
| 2022-01-27 | Reiterato | UBS | Neutral |
| 2021-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-30 | Reiterato | Deutsche Bank | Hold |
| 2021-07-30 | Reiterato | Jefferies | Buy |
| 2021-07-30 | Reiterato | Morgan Stanley | Overweight |
| 2021-07-30 | Reiterato | Oppenheimer | Outperform |
| 2021-07-30 | Reiterato | Stifel | Buy |
| 2021-07-30 | Reiterato | UBS | Neutral |
| 2021-07-30 | Reiterato | Wells Fargo | Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-04-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-11 | Reiterato | Canaccord Genuity | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Underperform |
| 2020-04-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Outperform |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-09-23 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-24 | Reiterato | BofA/Merrill | Buy |
| 2019-03-18 | Reiterato | Canaccord Genuity | Buy |
| 2019-01-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Hold |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-10-02 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Downgrade | Guggenheim | Buy → Neutral |
Mostra tutto
Edwards Lifesciences Corp Borsa (EW) Ultime notizie
Structural Heart Devices Market Set to Expand and Reach ~USD 25 Billion by 2032 Amid Rising Demand for Minimally Invasive Solutions | DelveInsight - GlobeNewswire Inc.
FTC Moves to Block Edwards Lifesciences’ $945 Million Acquisition of JenaValve Over Competition Concerns - MSN
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Edwards Lifesciences Stock: Analyst Estimates & Ratings - Barchart.com
FTC Sues to Block Edwards LifeSciences Medical Device Deal - MSN
FTC Sounds Alarm On Edwards’ Heart Device, M&A AttemptEdwards Lifesciences (NYSE:EW) - Benzinga
Edwards Lifesciences Leads Heart Device Market With Value Upside - Finimize
FTC seeks to block Edwards Lifesciences' acquisition of JenaValve - MSN
Edwards Lifesciences’ ALT-FLOW II Trial: A Key Update for Heart Failure Treatment - TipRanks
Baird Adjusts Price Target on Edwards Lifesciences to $81 From $79, Maintains Neutral Rating - MarketScreener
FTC moves to block Edwards’ acquisition of JenaValve Technology - Medical Buyer
FTC seeks to block Edwards Lifesciences’ acquisition of JenaValve - WKZO
FTC sues to block Edwards Lifesciences' $945M JenaValve deal - Daily Journal
Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insigh - GuruFocus
FTC sues to block Edwards Lifesciences purchase of JenaValve - MSN
FTC seeks to block Edwards Lifesciences' acquisition of JenaValve | Business Information & News | FE - Westlaw Today
South Africa Advocacy Groups Push to Reopen Vertex Antitrust Probe - PYMNTS.com
FTC Files Lawsuit to Block Edwards Lifesciences’ Purchase of JenaValve Technology - The Wall Street Journal
Edwards Lifesciences' deal with JenaValve would limit device access, US FTC says - MLex
FTC moves to block Edwards Lifesciences’ JenaValve acquisition - MassDevice
JenaValve Responds to FTC’s Action Against Proposed Edwards Lifesciences Acquisition - The Manila Times
Jenavalve disagrees with FTC's decision against proposed Edwards Lifesciences deal - MarketScreener
FTC seeks to block Edwards Lifesciences’ acquisition of JenaValve By Reuters - Investing.com
Edwards Lifesciences Comments on FTC’s Action to Block Proposed Acquisition of JenaValve - Yahoo Finance
Edwards Lifesciences Stock: Likely To See Sluggish Price Action Through 2027 - Benzinga
Edwards Lifesciences Corporation's (NYSE:EW) Stock Been Rising: Are Strong Financials Guiding The Market? - Yahoo Finance
How volatile is Edwards Lifesciences Corporation stock compared to the marketFree Stock Selection - Jammu Links News
Is Edwards Lifesciences Corporation a growth stock or a value stockHigh-octane investment gains - Jammu Links News
What catalysts could drive Edwards Lifesciences Corporation stock higher in 2025Build wealth with professional market analysis - Jammu Links News
Is it the right time to buy Edwards Lifesciences Corporation stockSuperior portfolio returns - Jammu Links News
How many analysts rate Edwards Lifesciences Corporation as a “Buy”Strongest growth potential - Jammu Links News
What are the technical indicators suggesting about Edwards Lifesciences CorporationMarket-crushing stock picks - Jammu Links News
Should I hold or sell Edwards Lifesciences Corporation stock in 2025Real Time Alerts For Fast Growth - Jammu Links News
Edwards Lifesciences’ SAPIEN 3 Valve Study: A Real-World Evaluation - TipRanks
Edwards Lifesciences’ PASCAL System: A Promising Update in Tricuspid Valve Repair - TipRanks
Agree To Purchase Edwards Lifesciences At $65, Earn 5.2% Using Options - Nasdaq
How Edwards Lifesciences Corporation stock reacts to Fed policy changesAI Powered High Return Stock Calls Dominate Watchlists - beatles.ru
Baron Health Care Fund Reacquired Edwards Lifesciences Corporation (EW) in Q2. Here’s Why - Yahoo Finance
Edwards Lifesciences’ SAPIEN 3 Study: A Market Game-Changer? - TipRanks
A Quick Look at Today's Ratings for Edwards Lifesciences(EW.US), With a Forecast Between $84 to $100 - 富途牛牛
Edwards Lifesciences Stock (EW) Opinions on Q2 Earnings Beat - Quiver Quantitative
Edwards Lifesciences’ Pivotal Trial: A Game-Changer for Tricuspid Valve Repair? - TipRanks
Edwards Lifesciences Corporation (NYSE:EW) Q2 2025 Earnings Call Transcript - Insider Monkey
Analysts upgrade Edwards as TAVR segment improves - MassDevice
BTIG upgrades Edwards Lifesciences stock to Buy on TAVR segment stability - Investing.com
Edwards Lifesciences prevails in heart valve dispute at the UPC - JUVE Patent
Edwards Lifesciences Corp Azioni (EW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.95%
0.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):